At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT)
In Brief
A clinical study evaluating Lattice stereotactic body radiation therapy and Peripheral blood for Cancer and Palliative Radiotherapy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Standard palliative radiotherapy regimens may provide limited durability of response in large tumors. Thus, there is a clinical need for a new approach. The Lattice SBRT approach will deliver 20 Gy in 5 fractions with partial volume simultaneous integrated boosts to 66.7 Gy. This is hypothesized to improve symptom response, local control, and better prime the tumor microenvironment for immune response compared with standard palliative radiotherapy doses. It is also hypothesized that this will be associated with less toxicity than the traditional homogenous SBRT plan delivered to a large tumor. Blood will be collected before and after Lattice SBRT for evaluation of the peripheral blood immune microenvironment.
Study Details
Timeline
Interventions
-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy